About us
Mölnlycke at a glance
A world-leading MedTech company
Mölnlycke has been at the forefront of change since 1849, pioneering radical innovation that improves the quality of life for patients and those who care for them, while reducing the environmental impact of healthcare. We provide effective solutions and we’re always on the lookout for new ways to improve. Focusing on wound care and surgical procedures, Mölnlycke is organised around four Business Areas: Wound care, Operating room solutions, Gloves and Antiseptics.
Placeholder for local about us content
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged.
-
Our purpose
Our purpose is to revolutionise care for people and planet. We drive change that improves the health and wellbeing of patients and those who care for them – while reducing the environmental footprint of healthcare.
Read more about our purpose -
Our strategy
Mölnlycke aims to become the market leader across all segments and geographies where the company operates. This ambition is firmly grounded in a strong portfolio of brands, as well as strong heritage of customer-insight driven innovations that improve the lives of people and planet.
Read more about our strategy
A strategic priority
We care about sustainability
Sustainability is a strategic priority at Mölnlycke and WeCare is our sustainability roadmap for 2030. It means creating shared value for all our stakeholders. It is a driver for growth, innovation and productivity and an essential part of our employee value proposition.
How we work with sustainabilityLatest news
-
EUR bond issue and tender announcement
Mölnlycke intends to issue a new 10-year EUR bond and launches a tender offer for the outstanding EUR 500m bond due February 2025.
-
Mölnlycke Health Care expands investment in Tamer Mölnlycke Care joint venture
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
-
Mölnlycke Health Care agrees to acquire leading wound cleansing manufacturer to consolidate its position as global leader in wound care
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.
-
Mölnlycke signs a EUR 350 million revolving credit facility
On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two one-year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017.
-
In 2023 Mölnlycke was awarded a gold medal for Sustainability by EcoVadis
The world’s largest and most trusted provider of business sustainability ratings - EcoVadis, has awarded Mölnlycke a gold medal for our focus on sustainability. They have ranked us in the top 3% of companies worldwide.
-
Mölnlycke integrated Annual Report 2023
Today we are delighted to announce the launch of the Mölnlycke integrated Annual Report 2023. Our dedication to revolutionising care for people and planet contributed to a very successful year with record high annual net sales of EUR 1,924 million and substantial improvements in profitability. We continue to report our sustainability achievements in accordance with the Global Reporting Initiative (GRI) standards.
-
Mölnlycke announces new partnership with burn survivors organisation Phoenix Society
Mölnlycke Health Care is pleased to announce our partnership with Phoenix Society for Burn Survivors.
-
Mölnlycke Health Care secures USD 400 Million in financing from SEK to support global expansion strategy
Stockholm/Gothenburg – 24 June, 2025. Mölnlycke Health Care and The Swedish Export Credit Corporation (SEK) have signed a USD 400 million financing agreement to support the healthcare company’s continued global growth and development.
-
Mölnlycke Health Care’s long-term target to reach net zero emissions validated by Science Based Targets initiative
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.